Prognosis
Eisai, Biogen Plunge After Report of Second Death in Groundbreaking Alzheimer’s Drug Trial
- Doctor blames death on combination with anti-clotting drug
- Drug not associated with increased death risk, Eisai says
This article is for subscribers only.
Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.
The case involved a 65-year-old woman who died of a massive brain hemorrhage after suffering a stroke and a type of brain swelling and bleeding in an Eisai trial, according to a report in Science magazine. The bleeding began after the patient received an anti-clotting drug, the report said. Brain swelling and bleeding have previously been linked to medicines that work like the Biogen-Eisai treatment.